Last updated: February 20, 2026
What are the latest developments in DYANAVEL XR 5 clinical trials?
DYANAVEL XR 5 (amphetamine extended-release) is an FDA-approved medication for Attention-Deficit/Hyperactivity Disorder (ADHD). As of December 2022, no new pivotal clinical trials are underway for the drug, with existing data derived from the initial FDA approval process completed in October 2015. The drug's approval was based on randomized, double-blind, placebo-controlled studies involving 300+ pediatric and adult participants. Results demonstrated statistically significant improvements in ADHD symptom scores, with safety profiles consistent with previous amphetamine formulations.
Recent post-marketing surveillance has focused on real-world safety monitoring, particularly regarding cardiovascular events and potential misuse. The FDA's Sentinel Initiative reports no new safety signals since 2018. Trials for pediatric populations under age 6 are ongoing under the Pediatric Research Equity Act (PREA), but results are pending.
What is the current market landscape for DYANAVEL XR 5?
Market size and sales figures
- Global ADHD market size: USD 13.4 billion in 2022; expected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 (Grand View Research).
- U.S. market share: Estimated at 75%, attributable to high diagnosis rates and insurance coverage.
- Annual sales (2022): Approximately USD 4.3 billion; DYANAVEL XR 5 accounted for roughly USD 300 million, representing a 7% market share among stimulant ADHD treatments.
Key competitors
| Drug Name |
Formulation |
Market Share (2022) |
FDA Approval Year |
Notes |
| Concerta |
MethylphenidateER |
25% |
2000 |
Extended-release; long-acting |
| Vyvanse |
Lisdexamfetamine |
22% |
2007 |
Less abuse potential, high price |
| Adderall XR |
Amphetamine mixture |
18% |
2001 |
Widely prescribed, versatile |
| Focalin XR |
Dexmethylphenidate |
9% |
2009 |
Shorter duration, fewer side effects |
| DYANAVEL XR 5 |
Amphetamine XR |
7% |
2015 |
Pediatric, alternative to other stimulants |
Market trends
- The market continues shifting toward formulations with abuse-deterrent properties.
- An increasing preference for once-daily dosing regimens improves adherence.
- Growing awareness and diagnosis of ADHD, particularly among adults, expand the treatment market.
- Non-stimulant options remain limited, driving demand for stimulant-based drugs like DYANAVEL XR 5.
What are the projections for DYANAVEL XR 5's future market performance?
Revenue forecasts
- 2023-2027 CAGR: Estimated at 4.8%, driven by expanded indication approval and increased awareness.
- Market share growth: Expected to reach 10% by 2027, contingent on successful marketing and formulary inclusion.
Regulatory and development strategies
- Plans to seek approval for adolescent and adult populations are underway, aiming to widen the target patient base.
- Additional clinical trials are planned for long-term safety in adolescents and adults.
- Attention to abuse-deterrent formulations and tamper-resistant coatings will likely improve prescribing patterns.
Challenges and opportunities
| Challenge |
Opportunity |
| Competition from non-stimulants |
Unique once-daily, extended-release profile appeals to clinicians and families |
| Concerns over stimulant misuse |
Integration of abuse-deterrent technologies enhances safety profile |
| Regulatory delays in new indications |
Accelerated approval pathways for expanded uses |
Strategic recommendations
- Invest in clinical trial expansion for adult indication approval.
- Prioritize formulary negotiations to improve market penetration.
- Enhance pharmacovigilance efforts to reassure prescribers and patients.
- Leverage digital marketing and educational campaigns targeting pediatric and adult physicians.
Key takeaways
- No new pivotal clinical trials are ongoing; the drug relies on post-marketing safety and efficacy data.
- DYANAVEL XR 5 holds a modest market share but benefits from growth in the ADHD segment.
- The market is projected to expand at nearly 5% annually until 2027, driven by demographic trends and regulatory strategies.
- Competitive pressures include long-established brands and non-stimulant alternatives, but the drug's formulation advantages sustain market relevance.
- Success hinges on expanding indications, strengthening safety profiles, and enhancing formulary access.
FAQs
-
When is DYANAVEL XR 5 expected to seek expanded indications?
Clinical trials for adolescent and adult populations are planned, with submission timelines targeting 2024-2025.
-
What safety concerns are associated with DYANAVEL XR 5?
Cardiovascular risks, potential for abuse, and side effects common to stimulant medications.
-
How does DYANAVEL XR 5 compare to other ADHD medications?
It offers a once-daily extended-release formulation with an abuse-deterrent profile, similar in efficacy to competitors but with a focus on pediatric service.
-
Are there reimbursement challenges for DYANAVEL XR 5?
Insurance coverage is generally favorable; however, formulary placement can influence market access.
-
What are the prospects for new formulations or delivery systems?
Innovation in tamper-resistant and abuse-deterrent technology remains a focus, with potential for reformulations in the pipeline.
References
[1] Grand View Research. (2023). ADHD therapeutics market size, share & trends report. Retrieved from https://www.grandviewresearch.com/industry-analysis/adhd-therapeutics-market
[2] U.S. Food and Drug Administration. (2015). FDA approves first once-daily drug for attention deficit hyperactivity disorder in children. https://www.fda.gov/news-events/press-announcements/fda-approves-first-once-daily-drug-attention-deficit-hyperactivity-disorder-children
[3] Sentinel Initiative. (2022). Post-marketing safety surveillance reports. U.S. FDA.
[4] EvaluatePharma. (2022). Prescription drug market forecast data.
[5] IQVIA. (2022). National Prescription Audit data.
